Acorda Therapeutics submits new regulatory filings for approval of Inbrija

Acorda Therapeutics announced the submission of new regulatory filings for the approval of Inbrija in six countries in Latin America by its partner Biopas Laboratories. Inbrija is indicated in the United States for the intermittent treatment of OFF episodes in adult patients with Parkinson’s disease, or PD, treated with carbidopa/levodopa. Biopas has submitted for marketing approval of Inbrija in Argentina, Colombia, Costa Rica, Ecuador, Panama and Peru. It expects to submit additional regulatory filings for approval of Inbrija in Chile in late 2023 and in Mexico and Brazil in 2024.